Using innovative nano-architectures to boost immune response against glioblastoma.
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
This study is testing a new treatment for glioblastoma that uses tiny particles to help boost your immune system so it can better fight the cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10928114 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of treatment for glioblastoma, a challenging brain cancer, by utilizing spherical nucleic acid (SNA) nano-architectures that act as immune system activators. The approach aims to enhance the body's natural immune response, particularly by stimulating natural killer (NK) cells and T cells, to target and destroy tumor cells more effectively. By improving the delivery and stability of immune-activating agents, this research seeks to overcome current limitations in glioblastoma therapies and is currently being tested in clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded well to existing treatments.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results with similar immune-activating approaches in other cancer models, indicating potential for success in this novel application.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Stegh, Alexander H. — Washington University
- Study coordinator: Stegh, Alexander H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.